Industry-Sponsored Symposium - A New Era in the Management of Gastroesophageal Reflux Disease

Supported by an independent educational grant from Phathom Pharmaceuticals.

Gastroesophageal reflux disease (GERD) is a highly prevalent, chronic gastrointestinal disorder that can result in serious complications if undertreated. Proton pump inhibitors (PPIs), the mainstay of GERD treatment, are generally safe and effective; however, some patients undergo PPI therapy for years but have recurrent or refractory symptoms. A new class of acid-suppressing therapies is in late-stage clinical development and nearing approval. In this live, interactive townhall, expert faculty will discuss the latest evidence regarding the diagnosis and management of GERD and erosive esophagitis (EE), including new medical therapies. Faculty will use patient cases to contextualize clinical information on GERD diagnosis and management that learners can apply in their own practices.

Open to all ACG 2023 attendees, industry-sponsored symposia provide additional educational opportunities. These programs are independent of the ACG 2023 Annual Scientific Meeting and Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.

Use the Register button or register at https://www.medscape.org/symposium/acg-ee-2023.